Antiangiogenic Nanomicelles for the Topical Delivery of Aflibercept to Treat Retinal Neovascular Disease

Antiangiogenic Nanomicelles for the Topical Delivery of Aflibercept to Treat Retinal Neovascular Disease

© 2021 Wiley-VCH GmbH.

Bibliographische Detailangaben
Veröffentlicht in:Advanced materials (Deerfield Beach, Fla.). - 1998. - 34(2022), 25 vom: 02. Juni, Seite e2108360
1. Verfasser: Zhao, Xinxin (VerfasserIn)
Weitere Verfasser: Seah, Ivan, Xue, Kun, Wong, Wendy, Tan, Queenie Shu Woon, Ma, Xiaoxiao, Lin, Qianyu, Lim, Jason Y C, Liu, Zengping, Parikh, Bhav Harshad, Mehta, Karishma N, Lai, Joel Weijia, Yang, Binxia, Tran, Kim Chi, Barathi, Veluchamy Amutha, Cheong, Kang Hao, Hunziker, Walter, Su, Xinyi, Loh, Xian Jun
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2022
Zugriff auf das übergeordnete Werk:Advanced materials (Deerfield Beach, Fla.)
Schlagworte:Journal Article angiogenesis inhibitors drug carriers drug delivery systems micelles ophthalmic solutions retinal diseases Angiogenesis Inhibitors Recombinant Fusion Proteins Vascular Endothelial Growth Factor A mehr... aflibercept 15C2VL427D Receptors, Vascular Endothelial Growth Factor EC 2.7.10.1
LEADER 01000naa a22002652 4500
001 NLM332645061
003 DE-627
005 20231225220006.0
007 cr uuu---uuuuu
008 231225s2022 xx |||||o 00| ||eng c
024 7 |a 10.1002/adma.202108360  |2 doi 
028 5 2 |a pubmed24n1108.xml 
035 |a (DE-627)NLM332645061 
035 |a (NLM)34726299 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Zhao, Xinxin  |e verfasserin  |4 aut 
245 1 0 |a Antiangiogenic Nanomicelles for the Topical Delivery of Aflibercept to Treat Retinal Neovascular Disease 
264 1 |c 2022 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 24.06.2022 
500 |a Date Revised 24.06.2022 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a © 2021 Wiley-VCH GmbH. 
520 |a The traditional intravitreal injection delivery of antivascular endothelial growth factor (anti-VEGF) to the posterior segment of the eye for treatment of retinal diseases is invasive and associated with sight-threatening complications. To avoid such complications, there has been significant interest in developing polymers for topical drug delivery to the retina. This study reports a nanomicelle drug delivery system made of a copolymer EPC (nEPCs), which is capable of delivering aflibercept to the posterior segment topically through corneal-scleral routes. EPC is composed of poly(ethylene glycol) (PEG), poly(propylene glycol) (PPG), and polycaprolactone (PCL) segments. In this study, aflibercept-loaded nEPCs (nEPCs + A) are capable of penetrating the cornea in ex vivo porcine eye models and deliver a clinically significant amount of aflibercept to the retina in laser-induced choroidal neovascularization (CNV) murine models, causing CNV regression. nEPCs + A also demonstrate biocompatibility in vitro and in vivo. Interestingly, this study also suggests that nEPCs have intrinsic antiangiogenic properties. The ability to deliver anti-VEGF drugs and the intrinsic antiangiogenic properties of nEPCs may result in synergistic effects, which can be harnessed for effective therapeutics. nEPCs may be a promising topical anti-VEGF delivery platform for the treatment of retinal diseases 
650 4 |a Journal Article 
650 4 |a angiogenesis inhibitors 
650 4 |a drug carriers 
650 4 |a drug delivery systems 
650 4 |a micelles 
650 4 |a ophthalmic solutions 
650 4 |a retinal diseases 
650 7 |a Angiogenesis Inhibitors  |2 NLM 
650 7 |a Recombinant Fusion Proteins  |2 NLM 
650 7 |a Vascular Endothelial Growth Factor A  |2 NLM 
650 7 |a aflibercept  |2 NLM 
650 7 |a 15C2VL427D  |2 NLM 
650 7 |a Receptors, Vascular Endothelial Growth Factor  |2 NLM 
650 7 |a EC 2.7.10.1  |2 NLM 
700 1 |a Seah, Ivan  |e verfasserin  |4 aut 
700 1 |a Xue, Kun  |e verfasserin  |4 aut 
700 1 |a Wong, Wendy  |e verfasserin  |4 aut 
700 1 |a Tan, Queenie Shu Woon  |e verfasserin  |4 aut 
700 1 |a Ma, Xiaoxiao  |e verfasserin  |4 aut 
700 1 |a Lin, Qianyu  |e verfasserin  |4 aut 
700 1 |a Lim, Jason Y C  |e verfasserin  |4 aut 
700 1 |a Liu, Zengping  |e verfasserin  |4 aut 
700 1 |a Parikh, Bhav Harshad  |e verfasserin  |4 aut 
700 1 |a Mehta, Karishma N  |e verfasserin  |4 aut 
700 1 |a Lai, Joel Weijia  |e verfasserin  |4 aut 
700 1 |a Yang, Binxia  |e verfasserin  |4 aut 
700 1 |a Tran, Kim Chi  |e verfasserin  |4 aut 
700 1 |a Barathi, Veluchamy Amutha  |e verfasserin  |4 aut 
700 1 |a Cheong, Kang Hao  |e verfasserin  |4 aut 
700 1 |a Hunziker, Walter  |e verfasserin  |4 aut 
700 1 |a Su, Xinyi  |e verfasserin  |4 aut 
700 1 |a Loh, Xian Jun  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Advanced materials (Deerfield Beach, Fla.)  |d 1998  |g 34(2022), 25 vom: 02. Juni, Seite e2108360  |w (DE-627)NLM098206397  |x 1521-4095  |7 nnns 
773 1 8 |g volume:34  |g year:2022  |g number:25  |g day:02  |g month:06  |g pages:e2108360 
856 4 0 |u http://dx.doi.org/10.1002/adma.202108360  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 34  |j 2022  |e 25  |b 02  |c 06  |h e2108360